EC Number |
Inhibitors |
Structure |
---|
1.3.1.72 | (1R,3aR,5aS,7S,9aS,9bR,11aR)-9a,11a-dimethyl-1-[(2R,3E)-4-phenylbut-3-en-2-yl]-2,3,3a,5,5a,6,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[a]phenanthren-7-ol |
- |
|
1.3.1.72 | (1R,3aR,5aS,7S,9aS,9bR,11aR)-9a,11a-dimethyl-1-[(2S)-1-oxopropan-2-yl]-2,3,3a,5,5a,6,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[a]phenanthren-7-yl acetate |
- |
|
1.3.1.72 | (20S)-pregn-5-ene-3,20-diol |
- |
|
1.3.1.72 | (2S)-2-((3S,5S,10S,13R,17R)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-N-methylpropanamide |
1 microM, 58% inhibition of total cholesterol production. Acts both on sterol reductoase and lathosterol oxidase |
|
1.3.1.72 | (2S)-2-((3S,5S,10S,13R,17R)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-N-propylpropanamide |
1 microM, 45% inhibition of total cholesterol production. Acts both on sterol reductoase and lathosterol oxidase |
|
1.3.1.72 | (2S)-2-((3S,5S,10S,13R,17R)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)propanamide |
1 microM, 75% inhibition of total cholesterol production |
|
1.3.1.72 | (2S)-2-[(1R,3aR,5aS,7S,9aS,9bR,11aR)-7-(acetyloxy)-9a,11a-dimethyl-2,3,3a,5,5a,6,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[a]phenanthren-1-yl]propanoic acid |
- |
|
1.3.1.72 | (2S)-2-[(1R,3aR,5aS,7S,9aS,9bR,11aR)-7-hydroxy-9a,11a-dimethyl-2,3,3a,5,5a,6,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[a]phenanthren-1-yl]-N-methylpropanamide |
- |
|
1.3.1.72 | (2S)-N-ethyl-2-((3S,5S,10S,13R,17R)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)propanamide |
1 microM, 61% inhibition of total cholesterol production |
|
1.3.1.72 | (3S,20S)-20-(aminomethyl)-pregn-7-en-3-yl acetate |
- |
|